Format

Send to

Choose Destination
React Oxyg Species (Apex). 2019 Jul;8(22):202-212.

3H-1,2-Dithiole-3-Thione as a Potentially Novel Therapeutic Compound for Sepsis Intervention.

Li YR1,2,3,4,5, Jia Z1,2,5, Zhu H6.

Author information

1
Department of Pharmacology, Campbell University Medical School, Buies Creek, NC 27506, USA.
2
Department of Pharmaceutical Sciences, Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC 27506, USA.
3
Virginia Tech-Wake Forest University School of Biomedical Engineering and Sciences, Blacksburg, VA 24061, USA.
4
Department of Biomedical Sciences and Pathobiology, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA.
5
Department of Biology, University of North Carolina College of Arts and Sciences, Greensboro, NC 27412, USA.
6
Department of Physiology and Pathophysiology, Campbell University Medical School, Buies Creek, NC 27506, USA.

Abstract

Through the history of modern medicine, bioactive components in natural products have been either employed directly as medicines or used as prototypes for synthetic drug development. This brief Research Highlights paper considers 3H-1,2-dithiole-3-thione (D3T), a member of the 1,2-dithiole-3-thiones-compounds which may naturally occur in cruciferous vegetables. Among 1,2-dithiole-3-thiones, D3T is the most potent member with regard to the capacity of inducing tissue defenses against oxidative and inflammatory stress. Oxidative and inflammatory stress is a major pathophysiological process involved in numerous human disorders, including cancer, cardiovascular diseases, neurodegeneration, and sepsis, to name just a few. This article surveys recent major research findings on D3T as an inducer of tissue antioxidative and antiinflammatory defenses and as a potential therapeutic modality for sepsis intervention.

KEYWORDS:

3H-1,2-Dithiole-3-thione; Anti-inflammation; Antioxidants; NF-κB; Nrf2; Sepsis

PMID:
31372498
PMCID:
PMC6675454

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center